Cardiac Marker Market Size Report | Share, Trends & Growth Drivers 2030

[Research Report] The cardiac marker market size is projected to grow from US$ 9.68 billion in 2022 to US$ 24.80 billion by 2031; it is projected to record a CAGR of 12.5% during 2022–2031.

Market Insights and Analyst View:

Cardiac markers are substances that are released into the bloodstream when there is damage or stress to the heart muscle. These markers are used to identify and monitor various heart conditions. These markers are measured via blood tests, and their levels can provide significant information about the functioning of the heart. Cardiac markers are of great significance in the timely and accurate diagnosis and treatment of various conditions, such as acute coronary syndrome, as well as the prognosis. With an aging global population and a growing incidence of cardiovascular diseases (CVD), there is an increasing demand for highly sensitive and specific cardiac marker assays that can facilitate early diagnosis and risk assessment. Additionally, the incorporation of artificial intelligence (AI) and machine learning algorithms into cardiac marker analysis enhances predictive accuracy and personalized treatment approaches. The technological advancements in the cardiac biomarker field have opened lucrative opportunities within the cardiac biomarker industry.

Growth Drivers:

According to the World Health Organization (WHO), CVDs are the leading cause of morbidity and mortality worldwide. CVDs include coronary heart disease, heart attack, cardiac ischemia, and others. The burden of CVD is rising worldwide, owing to various factors such as smoking, diabetes, obesity, and lifestyle changes. The other risk factors related to CVDs are high blood pressure, elevated cholesterol levels, and diabetes. Heart attacks and strokes are generally triggered by fatty deposits that block blood vessels, disrupting blood flow to the heart or brain. The growing prevalence of various CVDs is triggering the need for improved diagnostic methods.

As per the report published by the World Heart Federation projects, over half a billion people worldwide are living with CVD, accounting for 20.5 million deaths in 2021. According to the WHO, 17.9 million people die from CVD every year, which is 32% of all deaths worldwide. Per the American Heart Association, almost half of all adults in the US have a kind of CVD. 1 out of every 5 deaths in the US is due to CVD. Over 130 million people, i.e., 45.1% of the US population, are predicted to have a type of CVD by 2035.

According to the WHO, ~30 million people experience a stroke every year. According to the Centers for Disease Control and Prevention (CDC), every 40 seconds, an American has a heart attack. About 805,000 Americans have a heart attack every year, and ~605,000 of them for the first time. As per the Million Hearts 2021 data, ~1.5 million heart attacks (myocardial infarctions) and strokes occur in the US yearly. Per the CDC 2022 estimates, 20.1 million US adults have coronary artery disease. Moreover, the European Society of Cardiology reported that patients suffering from atrial fibrillation have a five-times greater risk of getting a stroke, and 20–30% of overall stroke cases in the country are caused by atrial fibrillation.

The rising incidences of cardiovascular disease necessitate the need for accurate and timely diagnosis. Pre-monitoring and pre-diagnosis can prevent most types of CVDs. Biomarkers are certain endogenous substances released into the blood during specific cardiovascular conditions, implying the abnormality of cardiac functioning. Therefore, the use of cardiac markers helps the individual to detect cardiovascular abnormality. Hence, the rising number of cardiovascular diseases is driving the growth of the cardiac markers market during the forecast period. 

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Cardiac Marker Market: Strategic Insights

Cardiac Marker Market

• Market Size 2023
  US$ 10.89 Billion
• Market Size 2031
  US$ 27.94 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type of Marker

• Troponin
• B-Type Natriuretic Peptide
• Creatine Kinase MB
• Myoglobin

Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome

End User

• Hospitals
• Diagnostic Laboratories
• Point-of-care Testing Facilities

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The global cardiac marker market is segmented on the basis of type of marker, indication, end user, and geography. Based on the type of marker, the market is segmented into troponin, b-type natriuretic peptide, creatine kinase MB, myoglobin, and others. Based on indication, the market is categorized into congestive heart failure, myocardial infarction, acute coronary syndrome, and others. In terms of end users, the cardiac marker market is classified into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The cardiac marker market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

The cardiac marker market, by type of marker, is segmented into troponin, b-type natriuretic peptide, creatine kinase MB, myoglobin, and others. The troponin segment held a significant share of the market in 2022. Troponins are proteins required for the contraction of cardiac muscles and skeletal muscles. A cardiac troponin test measures the levels of troponin T (TnT) or troponin I (TnI) proteins in the blood. These proteins appear in the blood only when the heart muscle has been damaged, such as during a heart attack. The cardiac troponin test detects damage to the heart muscle. The more damage to the heart muscle, the higher the level of troponin in the blood. Cardiac troponin is by far the most commonly used biomarker and has the highest known sensitivity. Troponins are a significant advancement in diagnosing and managing CVDs. When cardiac muscle cells sustain damage, these highly specialized proteins are discharged into the bloodstream. Troponin biomarkers are essential for diagnosing heart diseases, evaluating the seriousness of cardiac events, directing the selection of appropriate courses of action, and forecasting patient outcomes. Furthermore, by detecting traces of troponin in the blood, high-sensitivity troponin assays further improve the capacity to diagnose cardiac abnormalities early, even in the absence of clinical symptoms.

Based on indication, the cardiac marker market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment held a significant market share in 2022 due to the growing burden of disease in low- and middle-income countries compared to high-income countries. Factors like increased sedentary work and fast urbanization are driving the disease incidence. Tests for cardiac troponin T and I biomarkers have become the prime diagnostic methods for illness diagnosis. PrecisionCHD, an integrated epigenetic-genetic blood test for the early identification of coronary heart disease, was introduced by Cardio Diagnostics in February 2023. The test makes use of machine learning models that analyze genomic and epigenomic data, as well as genetic biomarkers and epigenetics. It links a patient's biomarker profile to modifiable risk factors that are important contributors to coronary heart disease, including smoking, diabetes, hypertension, and high cholesterol. However, the myocardial infarction segment is expected to register the fastest CAGR of the market during 2022–2031.

Based on the end user, the cardiac marker market is classified into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held a significant market share in 2022. Hospitals account for the largest share due to the high patient footfall and the availability of advanced diagnostic facilities. From the emergency department to inpatient care settings, cardiac biomarkers are essential in diagnosing acute cardiovascular events, identifying patient risk, and informing treatment decisions. These biomarkers' presence and accurate interpretation enable healthcare professionals to provide timely interventions and enhance patient outcomes.

Regional Analysis:

Based on geography, the cardiac marker market is primarily divided into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. North America captured a significant share of the global market in 2022. The cardiac marker market growth in North America is attributed to the increasing incidence of heart diseases, including CVDs, increasing spending on the research and development of CVD diagnostics, and a well-developed healthcare infrastructure. In 2022, the US held the largest share of the market in the region.

According to the Heart Disease and Stroke Statistics Fact Sheet 2022, every 40 seconds, a person in the US is expected to have a myocardial infarction. Likewise, the CDC September 2021 report stated that ~6.5 million people aged 40 and above in the country have peripheral arterial disease. According to the American Heart Association, one person dies every 34 seconds in the US from CVD. Almost 697,000 people in the country died from heart disease in 2021, i.e., one in every five deaths. Also, as per the report from the Heart and Stroke Foundation of Canada in February 2022, ~750,000 people are living with heart failure, and 100,000 individuals are diagnosed with heart failure annually in the country. Similarly, per the National Center for Health Statistics, in February 2023, ~695,000 people in the US died from heart disease in 2021. ~1.5 million heart attacks and strokes occur yearly in the country.

The increasing rates of CVD in the US have been attributed to the escalating prevalence of risk factors such as hypertension, high cholesterol levels, low HDL cholesterol, obesity, diabetes mellitus, abdominal obesity, and smoking. Heart disease costs the US about US$ 219 billion annually. This total cost includes the cost of health care services, medications, and premature death.

Further, the increasing market players' strategies in this region to introduce innovative and technologically advanced cardiac marker tests and devices are expected to contribute to the growth of the market. In July 2021, Beckman Coulter entered into definitive agreements with Quidel Corporation to acquire all rights related to the manufacture, distribution, and sale of a BNP assay for its Beckman Coulter analyzers for the treatment of congestive heart failure. Therefore, the above-mentioned factors are expected to contribute to the growth of the market in the region.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global cardiac marker market are listed below:

1. In July 2021, Beckman Coulter entered into a definitive agreement with Quidel Corporation to obtain all rights associated with the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Under the terms of the agreements, Quidel continues to manufacture and supply certain components related to the assay to Beckman Coulter. Beckman Coulter exclusively manufactures and sells the BNP assay to customers under the brand name Access BNP.
2. In April 2021, F. Hoffmann-La Roche launched a series of five new applications for their key cardiac biomarkers (cTnT-hs) in combination with their Elecsys technology. These biomarkers have been proven to be successful in managing CVD and can help clinicians diagnose heart attacks and manage heart failures in patients. This improves risk identification and diagnosis and allows the company to generate greater revenue from the existing products.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the cardiac biomarkers market are Abbott Diagnostics, Roche Diagnostics, bioMérieux SA, Thermo Fisher Scientific Inc., Beckman Coulter, Inc. (Danaher); Bio-Rad Laboratories; Trinity Biotech Plc; Creative Diagnostics; Diazyme Laboratories, Inc; Siemens AG, and Quidel Corporation. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the rising consumer demand worldwide. Cardiac biomarkers market companies emphasize various growth strategies such as collaboration, product launches, business expansions, and agreements, among others, to retain their position in the global market and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers and subsequently increases their cardiac marker market share.

Cardiac Marker Market Report Scope